Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Assessment of cell confluency confirms DNA-PK inhibition selectively synergizes with etoposide
Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma | Synapse